Pay in 4 interest-free payments of $6.32 Learn more
Ships within 48 hours · Estimated delivery Sep 30 - Oct 5
Drug Testing and Analysis, 7(1), 31-38
MOTS-c and GHK-Cu follow their own schedules based on mechanism
Often discussed for recovery, body composition, and healthy aging, and your provider may suggest combining them under guidance
TB-500 and Thymosin Beta-4 are also prohibited by WADA/USADA under S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics), applicable at all times both in-competition and out-of-competition TB-500 / Thymosin Beta-4 Clinical Trials: The RGN-352 and RGN-259 Programs RegeneRx Biopharmaceuticals has pursued two clinical development programs for Thymosin Beta-4, providing the most substantial human clinical data available for any TB-500-related compound: RGN-352 (Injectable Thymosin Beta-4 for Cardiac Repair): Phase 1 trial (completed): A double-blind, placebo-controlled study enrolled 40 healthy volunteers across four cohorts of 10 subjects each, testing escalating dose levels of intravenous Thymosin Beta-4 administered daily over 14 days
US$ 29.91
US$ 26.00
US$ 20.29
US$ 24.67
US$ 25.10
